MET and neoplasm: Strikingly, the patient tumor at second progression on osimertinib, although classified as MET polysomy (mean MET copies 4.8 and MET/CEP7 ratio of 1.5), showed approximately 26% MET amplified cells and focal areas with positive membranous phospho-MET staining (Fig. 4B, middle).